Revenue growth was lackluster due to pricing pressure in anti-infective therapy segment during the quarter. Its EBITDA margins declined to 14.3% primarily due to Higher Staff costs and Marketing Expenses. Net profit during Q2 FY12 stood at Rs …Henan Kangtai Pharmaceutical Group Corporation is the largest producer of Norfloxacin USP/IP/CP.
